{
  "source": "PA-Notification-Orencia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1075-14\nProgram Prior Authorization/Notification\nMedication *Orencia® (abatacept)\n*This program applies to the subcutaneous formulation of abatacept\nP&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,\n11/2011, 7/2012, 11/2012, 2/2014, 2/2015, 3/2016, 3/2017, 8/2017, 8/2018,\n8/2019, 8/2020, 8/2021, 8/2022, 7/2023, 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nOrencia (abatacept) is a selective T-cell costimulation modulator indicated for the treatment\nof adult patients with moderately to severely active rheumatoid arthritis (RA), patients 2\nyears of age and older with moderately to severely active polyarticular juvenile idiopathic\narthritis (JIA), and patients 2 years of age and older with active psoriatic arthritis (PsA).\nConcomitant use of Orencia with other immunosuppressives [e.g., biologic disease-\nmodifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not\nrecommended.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Orencia will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),\nOlumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Orencia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Orencia therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),\nOlumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz\n(tofacitinib)]\nAuthorization will be iss",
    "eted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),\nOlumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\nB. Juvenile Idiopathic Arthritis (JIA)\n1. Initial Authorization\na. Orencia will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic\narthritis.\n-AND-\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),\nOlumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Orencia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Orencia therapy\n-AND-\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),\nOlumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\nC. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Orencia will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx\n(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Otezla (apremilast),\nRinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara\n(ustekinumab), Taltz (ixekizumab), Tremfya (guselkumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Orencia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Orencia therapy\n-AND-\n(2) Patient is n",
    " issued for 12 months.\n2. Reauthorization\na. Orencia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Orencia therapy\n-AND-\n(2) Patient is not receiving Orencia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx\n(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Otezla (apremilast),\nRinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara\n(ustekinumab), Taltz (ixekizumab), Tremfya (guselkumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Supply limits, Medical Necessity and/or Step Therapy may be in place.\n• The intravenous infusion is typically covered under the medical benefit. Please refer to the\nUnited Healthcare Medical Benefit Drug Policy for Orencia.\n4. References:\n1. Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb; May 2024.\nProgram Prior Authorization/Notification - Orencia (abatacept)\nChange Control\n2/2014 Background updated. Concomitant therapy criterion condensed to list\nfour biologic DMARDs and revised to include Xeljanz. Reauthorization\ncriteria revised to standard verbiage and to include concomitant therapy\ncriterion. Extended reauthorization duration to 24 months.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated clinical rules and background.\n3/2016 Annual review with no change to the coverage criteria. Updated\nstatement regarding scope of the program. Added reference to UHC\ndrug policy for intravenous infusions. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3\n3/2017 Annual review with no change to coverage criteria. Updated\nbackground and references.\n8/2017 Added psoriatic arthritis to cover",
    "ons. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3\n3/2017 Annual review with no change to coverage criteria. Updated\nbackground and references.\n8/2017 Added psoriatic arthritis to coverage criteria. Updated background and\nreferences.\n8/2018 Annual review. Added Olumiant (baricitinib) to applicable criteria.\nUpdated background.\n8/2019 Annual review with no change to coverage criteria. Updated\nbackground and references.\n8/2020 Annual review. Updated reauthorization duration to 12 months.\nUpdated background and references.\n8/2021 Annual review with no changes to coverage criteria.\n8/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote. Updated background and reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n1/2024 Updated Background for updated indication for PsA for patients 2 years\nof age and older. Updated reference.\n1/2025 Annual review. Updated examples with no change to clinical intent.\nUpdated reference.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}